Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study
暂无分享,去创建一个
K. Anstrom | C. O'connor | G. Felker | J. Butler | Adrian F. Hernandez | D. Mann | M. LeWinter | K. Margulies | W. Tang | S. McNulty | S. Goldsmith | M. Redfield | M. Konstam | T. Cappola | E. Ofili | M. Dunlap | M. Semigran | M. Givertz | Kerry L Lee | M. Shah | H. Haddad | A. Deswal | M. Saltzberg | Adrian F. Hernandez | Steven R. Goldsmith | Marvin A. Konstam | Christopher M. O’Connor | Elizabeth O. Ofili | Douglas L. Mann | Martin M Lewinter | W. H. W. Tang | Kerry L. Lee | Kenneth B. Margulies | Mark E. Dunlap | Mitchell T. Saltzberg | Martin M. Lewinter | W. W. Tang
[1] Benjamin R. Szwejkowski,et al. 159 ALLOPURINOL REDUCES LEFT VENTRICULAR MASS IN PATIENTS WITH TYPE 2 DIABETES AND LEFT VENTRICULAR HYPERTROPHY , 2013, Heart.
[2] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[3] I. Piña,et al. Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial). , 2013, The American journal of cardiology.
[4] E. Braunwald,et al. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients: Design and Rationale of the EXACT-HF Study , 2013, Circulation. Heart failure.
[5] P. Ponikowski,et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial , 2013, European journal of heart failure.
[6] J. Hare,et al. Nitroso-redox imbalance affects cardiac structure and function. , 2013, Journal of the American College of Cardiology.
[7] Benjamin R. Szwejkowski,et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. , 2013, Journal of the American College of Cardiology.
[8] J. Januzzi,et al. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. , 2013, Circulation.
[9] J. Hare,et al. Hydralazine and Organic Nitrates Restore Impaired Excitation-Contraction Coupling by Reducing Calcium Leak Associated with Nitroso-Redox Imbalance* , 2013, The Journal of Biological Chemistry.
[10] Z. Coufal,et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. , 2012, Journal of critical care.
[11] A. Keren,et al. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. , 2012, Journal of cardiac failure.
[12] A. Wu,et al. Multiple Biomarkers for Risk Prediction in Chronic Heart Failure , 2012, Circulation. Heart failure.
[13] P. Bottomley,et al. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. , 2012, Journal of the American College of Cardiology.
[14] Harlan M Krumholz,et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. , 2011, JAMA.
[15] P. Stone. Allopurinol a new anti-ischemic role for an old drug. , 2011, Journal of the American College of Cardiology.
[16] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[17] J. Brophy,et al. Gout, allopurinol use, and heart failure outcomes. , 2010, Archives of internal medicine.
[18] S. Anker,et al. Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Crossover Preliminary Study , 2010, Circulation. Heart failure.
[19] J. Choe,et al. Serum Cystatin C is a Potential Endogenous Marker for the Estimation of Renal Function in Male Gout Patients with Renal Impairment , 2009, Journal of Korean medical science.
[20] A. Struthers,et al. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. , 2009, Journal of the American College of Cardiology.
[21] Joanne Brown,et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. , 2008, Journal of the American College of Cardiology.
[22] H. Y. Lee,et al. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? , 2008, Singapore medical journal.
[23] G. Lamb,et al. Hydroxyl radical and glutathione interactions alter calcium sensitivity and maximum force of the contractile apparatus in rat skeletal muscle fibres , 2008, The Journal of physiology.
[24] S. Schneeweiss,et al. Repeated hospitalizations predict mortality in the community population with heart failure. , 2007, American heart journal.
[25] S. Russell,et al. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels , 2007, Heart.
[26] A. Struthers,et al. High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid , 2006, Circulation.
[27] D. Mozaffarian,et al. The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.
[28] A. Struthers,et al. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure , 2005, Heart.
[29] Joanne Brown,et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure , 2004, Expert opinion on investigational drugs.
[30] P. Ponikowski,et al. Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging , 2003, Circulation.
[31] A. Struthers,et al. Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure , 2002, Circulation.
[32] D. Kass,et al. Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.
[33] M. Packer,et al. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. , 2001, Journal of cardiac failure.
[34] K. Dickstein,et al. Assessing the effect of exercise training in men with heart failure; comparison of maximal, submaximal and endurance exercise protocols. , 2001, European heart journal.
[35] J. Spertus,et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. , 2000, Journal of the American College of Cardiology.
[36] D. Kass,et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. , 1999, Circulation research.
[37] S. Anker,et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. , 1997, European heart journal.
[38] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[39] Sénait Judge-Yoakam. Hennepin County Medical Center , 2017 .
[40] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[41] R. Day,et al. Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol , 2007, Clinical pharmacokinetics.
[42] Hiroyuki Tsutsui,et al. [Oxidative stress and heart failure]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[43] D.,et al. Regression Models and Life-Tables , 2022 .